26429 Antimicrobial Susceptibility, Acid-Fast Bacilli, Rapidly Growing, Varies (MMLRG)

​Acid-Fast Bacilli (AFB), AFB (Acid-Fast Bacilli), Antibiotic Susceptibility, Bacillus, Acid-Fast, MIC (Minimum Inhibitory Concentration), Minimum Inhibitory Concentration (MIC), Mycobacteria Antimicrobial Susceptibility (MIC) (Minimum Inhibitory Concentration), Mycobacterium abscessus Susceptibility Testing, Mycobacterium chelonae Susceptibility Testing, Mycobacterium fortuitum Susceptibility Testing, Mycobacterium mucogenicum Susceptibility Testing, Rapid Growing Mycobacteria to Antimicrobial Agents, Susceptibility Testing, Clofazimine

​Antimicrobials tested in this assay are amikacin, cefoxitin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.

​Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel.

​Organism must be in pure culture, actively growing on Middlebrook 7H10 agar slant or other appropriate media. 

​CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies must also be ordered and will be charged separately unless identification of organism is provided by the client.

Specimen source is required.

Identification to the species level is required for Mycobacterium species in order for the correct antimicrobial susceptibility drug panel to be selected. Identification to the genus level is sufficient for Nocardia species and other aerobic actinomycetes (eg, Gordonia species, Rhodococcus species).

Shipping Instructions

1. See Infectious Specimen Shipping Guidelines in Special Instructions.

2. Place specimen in a large infectious container (T146) and label as an etiologic agent/infectious substance.

Agar plate

​There are more than 100 species of rapidly growing mycobacteria and many are significant human pathogens (eg, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum). Rapidly growing mycobacteria cause a variety of infections including pulmonary infections, skin and soft tissue infections, and disseminated disease. Antimicrobial susceptibility testing of clinically significant rapidly growing mycobacteria is important to help guide patient care.

Antimicrobials tested in this assay are amikacin, cefoxitin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.

​Results are reported as the minimum inhibitory concentration in micrograms/mL. Interpretive criteria (susceptible, intermediate, or resistant) are reported according the Clinical and Laboratory Standards Institute (CLSI) guidelines.